Sebia Acquires Autoimmune and Infectious Diseases Diagnostic Company Zeus Scientific

Sebia (Lisses, France), a global specialty diagnostic company providing innovative solutions for screening and diagnostics in oncology, metabolic diseases, genetic disorders and autoimmune diseases, has acquired Zeus Scientific, Inc. (Branchburg, NJ, USA), an In Vitro Diagnostic (IVD) company specialized in autoimmune and infectious diseases technologies. The financial terms of the agreement were not disclosed.

Sebia is a world-leading provider of clinical protein electrophoresis equipment and reagents, a technology used for in vitro diagnostic testing. Its systems analyze proteins in order to screen and monitor various diseases and conditions; primarily oncology (multiple myeloma) and metabolic disorders such as diabetes, also hemoglobinopathy and rare pathologies. Following the acquisition of Orgentec, Corgenix and Arotec in 2021, Sebia now develops and markets innovative solutions for autoimmunity diagnostics.

Zeus is a global company focusing on the development, production and marketing of in vitro diagnostic tests to detect autoimmune and infectious diseases, available in several different technology applications. Clinical areas include inflammatory rheumatic diseases, serological detection of autoimmune vasculitis, thyroid diagnostics, gastroenterology and a number of infectious diseases, with a strong focus on Lyme disease. Zeus will provide synergies and expand Sebia’s capabilities and product portfolio in autoimmunity, with a strong footprint in the U.S.

“Through this acquisition, we will be able to expand Sebia’s capabilities to provide high-value solutions to our customers and patients,” said Jean-Marc Chermette, Sebia’s president and CEO. “Zeus Scientific has developed a strong expertise in autoimmunity and infectious diseases. There are many parallels in our respective R&D programs, as well as benefits for the development of our global commercial network. With this acquisition, Sebia is reinforcing its operations and footprint in the United States, the largest IVD market. I am very pleased to welcome Zeus Scientific associates to the Sebia Group and look forward to a strong collaboration to accelerate innovation and global growth.”

“We are extremely pleased to join the Sebia team,” said Scott Tourville, CEO of Zeus Scientific. “Its world-leading position in clinical protein electrophoresis and in vitro diagnostic testing makes Sebia the ideal company to continue to build on Zeus Scientific’s 46-year legacy of diagnostic innovation.”

Related Links:
Sebia 
Zeus Scientific, Inc. 

Visit expo >

Gold Member

Serological Pipet Controller

PIPETBOY GENIUS

Verification Panels for Assay Development & QC
Seroconversion Panels

New

Respiratory Bacterial Panel

Real Respiratory Bacterial Panel 2

New

Community-Acquired Pneumonia Test

RIDA UNITY CAP Bac